קו-דיובאן 16025 מג טבליות מצופות Ізраїль - іврит - Ministry of Health

קו-דיובאן 16025 מג טבליות מצופות

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

פוסאלאן פעם בשבוע 70 מג Ізраїль - іврит - Ministry of Health

פוסאלאן פעם בשבוע 70 מג

organon pharma israel ltd., israel - alendronate as sodium - טבליה - alendronate as sodium 70 mg - alendronic acid - alendronic acid - fosalan is indicated for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures). treatment to increase bone mass in men with osteoporosis.

מונטהלוקאסט טבע   10 מג Ізраїль - іврит - Ministry of Health

מונטהלוקאסט טבע 10 מג

abic marketing ltd, israel - montelukast as sodium - טבליות מצופות פילם - montelukast as sodium 10 mg - montelukast - montelukast - montelukast teva is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. montelukast teva is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast teva and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast teva is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and adolescents 15 years of age and older.

מונטהלוקאסט טבע ® 4 מ"ג Ізраїль - іврит - Ministry of Health

מונטהלוקאסט טבע ® 4 מ"ג

salomon,levin & elstein ltd - montelukast as sodium 4 mg - chewable tablets - montelukast - montelukast teva is indicated in pediatric patients 2 to 5 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction.montelukast teva is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast teva and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast teva is indicated for the relief of symptoms of seasonal allergic rhinitis in pediatric patients 2 to 5 years of age and older.

מונטהלוקאסט טבע ® 5 מ"ג Ізраїль - іврит - Ministry of Health

מונטהלוקאסט טבע ® 5 מ"ג

salomon,levin & elstein ltd - montelukast as sodium 5 mg - chewable tablets - montelukast - montelukast teva is indicated in pediatric patients 6 to 14 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction.montelukast teva is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast teva and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast teva is indicated for the relief of symptoms of seasonal allergic rhinitis in pediatric patients 6 to 14 years of age and older.

מונטהלוקאסט אינובמד 5 מ"ג Ізраїль - іврит - Ministry of Health

מונטהלוקאסט אינובמד 5 מ"ג

inovamed ltd - montelukast as sodium 5 mg - chewable tablets - montelukast - montelukast inovamed is indicated in pediatric patients 6 to 14 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction.montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 6 to 14 years of age.

מונטהלוקאסט אינובמד 4 מ"ג Ізраїль - іврит - Ministry of Health

מונטהלוקאסט אינובמד 4 מ"ג

inovamed ltd - montelukast as sodium 4 mg - chewable tablets - montelukast - montelukast inovamed is indicated in pediatric patients 2 to 5 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 to 5 years of age.

מונטהלוקאסט אינובמד 10 מ"ג Ізраїль - іврит - Ministry of Health

מונטהלוקאסט אינובמד 10 מ"ג

inovamed ltd - montelukast as sodium 10 mg - film coated tablets - montelukast - montelukast inovamed is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction.montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and adolescents 15 years of age and older.

פוסאוונס 70מג5600 יחבל טבליות Ізраїль - іврит - Ministry of Health

פוסאוונס 70מג5600 יחבל טבליות

merck sharp & dohme israel ltd - alendronic acid as alendronate sodium trihydrate; colecalciferol - טבליה - colecalciferol 140 mcg; alendronic acid as alendronate sodium trihydrate 70 mg - colecalciferol - colecalciferol - fosavance is indicated for : treatment of osteoporosis in postmenopausal women: for the treatment of osteoporosis, fosavance increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). treatment to increase bone mass in men with osteoporosis.

קלקסן Ізраїль - іврит - Ministry of Health

קלקסן

sanofi israel ltd - enoxaparin sodium - תמיסה להזרקה - enoxaparin sodium 100 mg/ml ml - enoxaparin - enoxaparin - enoxaparin sodium is an anti-coagulant. at dosesof 20 mg and 40 mg it is indicated for: - prophylactic treatment of thrombo-embolic disorders of venous origin and in particular in orthopedic surgery or in general surgery. - prevention of thrombus formation in the extra-corporeal circulation during hemodialysis. at dosege of 40 mg the indications are: - prophylactic treatment of deep vein thrombosis in patients who are bedridden due to an acute medial disorder: - heart failure (hyha class iii or iv) - acute respiratory failure - episode of acute infection or acute rheumatic disorder combined with at least one other venous thromboembolic risk factor. at high doses of 60, 80 ,100 mg clexan is indicated for: -treatment of deep vein thrombosis (dvt). - treatment of unstable angina and non-q-wave myocardial infaction administered concurrently with aspirin. - treatment of pulmonary embolism.treatment of acute st- segment elevation myocardial infarction, in combination with a thrombolytic agent in patients eligible o